GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Capex-to-Operating-Income

EV Biologics (EV Biologics) Capex-to-Operating-Income : 0.00 (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

EV Biologics's Capital Expenditure for the three months ended in Dec. 2017 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2017 was $4.87 Mil.

Hence, EV Biologics's Capex-to-Operating-Income for the three months ended in Dec. 2017 was 0.00.


EV Biologics Capex-to-Operating-Income Historical Data

The historical data trend for EV Biologics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Capex-to-Operating-Income Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Capex-to-Operating-Income
1.00 0.06 0.16 11.50 -

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.10 - -

Competitive Comparison of EV Biologics's Capex-to-Operating-Income

For the Biotechnology subindustry, EV Biologics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where EV Biologics's Capex-to-Operating-Income falls into.



EV Biologics Capex-to-Operating-Income Calculation

EV Biologics's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2017 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.929) / -3.93
=N/A

EV Biologics's Capex-to-Operating-Income for the quarter that ended in Dec. 2017 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 4.871
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics  (OTCPK:YECO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


EV Biologics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of EV Biologics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates on NFT Minting

By ACCESSWIRE ACCESSWIRE 09-28-2021

EV Biologics is now Pink Current

By ACCESSWIRE ACCESSWIRE 06-14-2021

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021

EV Biologics Signs Listing Agreement With INX

By ACCESSWIRE ACCESSWIRE 11-11-2021

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Updates on FINRA Filings

By ACCESSWIRE ACCESSWIRE 03-09-2022